SAB Biotherapeutics Inc. Common Stock is a leading biotechnology company specializing in the development of human antibody therapeutics. With a focus on rapidly producing significant quantities of antibodies using its proprietary DiversitAb™ platform, it aims to address critical unmet medical needs and improve patient outcomes.
